Working together to develop a screening platform to enhance the detection and management of Alzheimer’s disease.
PREDICTOM is an international across sector initiative to bring dementia diagnostics closer to the public through a customisable cognitive and biomarker screening platform.
Latest news
News
Unlocking Alzheimer's Progress: Advancing Diagnosis and Treatment Through Interdisciplinary Expertise
Timo Schirmer, Director of the MR Applied Science Laboratory at GE HealthCare, speaks about his role in PREDICTOM as industry lead and reflects on the project's goals to improve early diagnosis of Alzheimer's disease: “ By providing a tool that can easily identify those people with early signs of dementia, we expect to significantly decrease the personal and financial burden of dementia in Europe and around the world.”
News
Involving members of the public to improve Alzheimer's research and remove stigma
Sarah Campill, Public Involvement Officer at Alzheimer Europe, discusses her contribution to PREDICTOM and the importance of involving members of the public in Alzheimer's research. ‘It is about giving back power. The more we talk about Alzheimer’s disease, the less scary it gets.’
News
Transforming Alzheimer's care by bringing diagnosis to the household and primary care
In the first installment of theses interview series, we speak with Dag Aarsland, Professor of Old Age Psychiatry at King's College London and research lead at Stavanger University Hospital. Dag is the academic lead in PREDICTOM and coordinator of its clinical trial. He explains: 'As PREDICTOM's scientific lead, I make sure the scientific activities in the project are running smoothly. I also try to detect any issues we face early on and solve any bottlenecks that come up.'
Our mission
PREDICTOM will identify scalable biosignatures for early and accurate diagnosis of Alzheimer’s disease and personalized preventive interventions.